好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Galcanezumab effects on incidence of headache after occurrence of triggers, prodromes, and aura in responders, non-responders, super-responders and super non-responders
Headache
P12 - Poster Session 12 (5:30 PM-6:30 PM)
2-012
The goal of this study was to determine effects of galcanezumab on premonitory symptoms, triggers and auras’ ability to initiate a headache in treatment-responders (>50%), super-responders (>70%) non-responders (<50%) and super non-responders (<30% reduction in monthly migraine days).

Migraine can progress through several phases: prodrome, aura, attack and postdrome.

Participants were administered electronic daily headache diary to document migraine days and associated symptoms before and after treatment for 3 months. Detailed questionnaires/interviews were used to document changes in premonitory symptoms followed by headache, and  incidence of triggers that initiate a headache.

Of the 64 participants,  we found that after treatment: (a) incidence of prodromes followed by headache decreased 48% in responders vs. 28% in non-responders, and 50% in super-responders vs. 12% in super non-responders; (b) incidence of visual and sensory auras followed by headache reduced among all groups, except the super non-responder group; (c) the number of triggers followed by headache decreased by 38% in responders vs. 13% in non-responders, and 31% in super-responders vs. 4% in super non-responders; (d) premonitory symptoms: incidence of headache following cognitive impairment and irritability reduced in responders and super-responders only, whereas incidence of headache after fatigue, nausea and vertigo reduced in all groups except among the super non-responders; and (e) triggers: incidence of headache following not drinking enough and being too hot reduced in responders and super-responders, whereas incidence of headache after stress, sleep and light reduced in all groups except the super non-responders.

These findings suggest that even a mild decrease in migraine frequency is sufficient to partially reverse pain impact on the excitability and responsivity of neurons involved in the generation of certain migraine prodromes and triggers. Clinically, these findings provide further justification for lowering the definition threshold of responders from >50 to >30% reduction in migraine day/month.

Authors/Disclosures
Sait Ashina, MD (Beth Israel Deaconess Medical Center, Harvard Medical School)
PRESENTER
Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theranica. Dr. Ashina has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Ashina has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Ashina has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer.
Agustin Melo Carrillo, MD, PhD (Beth Israel Deaconess Medical Center. Harvard Medical School) Dr. Melo Carrillo has nothing to disclose.
No disclosure on file
No disclosure on file
David Borsook (Masachusetts General Hospital) No disclosure on file
Rami Burstein, PhD (Beth Isreal Deacones Medical Center) Dr. Burstein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan. Dr. Burstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eli Lilly. Dr. Burstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Burstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Burstein has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Burstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Dr. Reddy. Dr. Burstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Burstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurolief. Dr. Burstein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Percept. Dr. Burstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Burstein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Theranica. The institution of Dr. Burstein has received research support from Allergan. The institution of Dr. Burstein has received research support from Teva. The institution of Dr. Burstein has received research support from Eli Lilly. The institution of Dr. Burstein has received research support from Dr. Reddy.